PPARG and partial lipodystrophy: Third, while the beneficial effect of thiazolidinediones, one of very few drugs that clearly improve insulin sensitivity, was recognized before the discovery of PPARG mutations in patients with partial lipodystrophy, this link attests to the potential for human genetics to inform drug discovery.